 | • レポートコード：QFJ1-4927 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、全身性アミロイドーシスの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（原発性全身性アミロイドーシス（PSA）、続発性全身性アミロイドーシス、その他）、用途別市場規模（病院、診療所、研究所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・全身性アミロイドーシスの市場動向 ・企業の競争状況、市場シェア ・全身性アミロイドーシスの種類別市場規模と予測2016-2027（原発性全身性アミロイドーシス（PSA）、続発性全身性アミロイドーシス、その他） ・全身性アミロイドーシスの用途別市場規模と予測2016-2027（病院、診療所、研究所、その他） ・全身性アミロイドーシスの北米市場規模2016-2027（アメリカ、カナダ） ・全身性アミロイドーシスの欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・全身性アミロイドーシスのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・全身性アミロイドーシスの中南米市場規模2016-2027（メキシコ、ブラジル） ・全身性アミロイドーシスの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Celgene Corporation(Bristol-Myers Squibb)、Prothena Corporation PLC、TheraPharm Deutschland GmbH、Johnson & Johnson、Amgen Inc.、Onclave Therapeutics Limited、Pfizer Inc.、GlaxoSmithKline plc、Alnylam Pharmaceuticals, Inc.、Takeda Pharmaceutical Company Limited、Allergan plc、AbbVie Inc.） ・結論 |
Amyloidosis is a clinical disorder caused by extracellular or intracellular deposition of insoluble abnormal amyloid fibrils that affect the normal function of tissues.
Market Analysis and Insights: Global Systemic Amyloidosis Market
The global Systemic Amyloidosis market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Systemic Amyloidosis market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Systemic Amyloidosis market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Systemic Amyloidosis market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Systemic Amyloidosis market.
Global Systemic Amyloidosis Scope and Market Size
Systemic Amyloidosis market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Systemic Amyloidosis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Primary Systemic Amyloidosis (PSA)
Secondary Systemic Amyloidosis
Others
Segment by Application
Hospitals
Clinics
Research Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Celgene Corporation(Bristol-Myers Squibb)
Prothena Corporation PLC
TheraPharm Deutschland GmbH
Johnson & Johnson
Amgen Inc.
Onclave Therapeutics Limited
Pfizer Inc.
GlaxoSmithKline plc
Alnylam Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Allergan plc
AbbVie Inc.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Systemic Amyloidosis Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Primary Systemic Amyloidosis (PSA)
1.2.3 Secondary Systemic Amyloidosis
1.2.4 Others
1.3 Market by Application
1.3.1 Global Systemic Amyloidosis Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Research Institutes
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Systemic Amyloidosis Market Perspective (2016-2027)
2.2 Systemic Amyloidosis Growth Trends by Regions
2.2.1 Systemic Amyloidosis Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Systemic Amyloidosis Historic Market Share by Regions (2016-2021)
2.2.3 Systemic Amyloidosis Forecasted Market Size by Regions (2022-2027)
2.3 Systemic Amyloidosis Industry Dynamic
2.3.1 Systemic Amyloidosis Market Trends
2.3.2 Systemic Amyloidosis Market Drivers
2.3.3 Systemic Amyloidosis Market Challenges
2.3.4 Systemic Amyloidosis Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Systemic Amyloidosis Players by Revenue
3.1.1 Global Top Systemic Amyloidosis Players by Revenue (2016-2021)
3.1.2 Global Systemic Amyloidosis Revenue Market Share by Players (2016-2021)
3.2 Global Systemic Amyloidosis Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Systemic Amyloidosis Revenue
3.4 Global Systemic Amyloidosis Market Concentration Ratio
3.4.1 Global Systemic Amyloidosis Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Systemic Amyloidosis Revenue in 2020
3.5 Systemic Amyloidosis Key Players Head office and Area Served
3.6 Key Players Systemic Amyloidosis Product Solution and Service
3.7 Date of Enter into Systemic Amyloidosis Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Systemic Amyloidosis Breakdown Data by Type
4.1 Global Systemic Amyloidosis Historic Market Size by Type (2016-2021)
4.2 Global Systemic Amyloidosis Forecasted Market Size by Type (2022-2027)
5 Systemic Amyloidosis Breakdown Data by Application
5.1 Global Systemic Amyloidosis Historic Market Size by Application (2016-2021)
5.2 Global Systemic Amyloidosis Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Systemic Amyloidosis Market Size (2016-2027)
6.2 North America Systemic Amyloidosis Market Size by Type
6.2.1 North America Systemic Amyloidosis Market Size by Type (2016-2021)
6.2.2 North America Systemic Amyloidosis Market Size by Type (2022-2027)
6.2.3 North America Systemic Amyloidosis Market Size by Type (2016-2027)
6.3 North America Systemic Amyloidosis Market Size by Application
6.3.1 North America Systemic Amyloidosis Market Size by Application (2016-2021)
6.3.2 North America Systemic Amyloidosis Market Size by Application (2022-2027)
6.3.3 North America Systemic Amyloidosis Market Size by Application (2016-2027)
6.4 North America Systemic Amyloidosis Market Size by Country
6.4.1 North America Systemic Amyloidosis Market Size by Country (2016-2021)
6.4.2 North America Systemic Amyloidosis Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Systemic Amyloidosis Market Size (2016-2027)
7.2 Europe Systemic Amyloidosis Market Size by Type
7.2.1 Europe Systemic Amyloidosis Market Size by Type (2016-2021)
7.2.2 Europe Systemic Amyloidosis Market Size by Type (2022-2027)
7.2.3 Europe Systemic Amyloidosis Market Size by Type (2016-2027)
7.3 Europe Systemic Amyloidosis Market Size by Application
7.3.1 Europe Systemic Amyloidosis Market Size by Application (2016-2021)
7.3.2 Europe Systemic Amyloidosis Market Size by Application (2022-2027)
7.3.3 Europe Systemic Amyloidosis Market Size by Application (2016-2027)
7.4 Europe Systemic Amyloidosis Market Size by Country
7.4.1 Europe Systemic Amyloidosis Market Size by Country (2016-2021)
7.4.2 Europe Systemic Amyloidosis Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Systemic Amyloidosis Market Size (2016-2027)
8.2 Asia-Pacific Systemic Amyloidosis Market Size by Type
8.2.1 Asia-Pacific Systemic Amyloidosis Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Systemic Amyloidosis Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Systemic Amyloidosis Market Size by Type (2016-2027)
8.3 Asia-Pacific Systemic Amyloidosis Market Size by Application
8.3.1 Asia-Pacific Systemic Amyloidosis Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Systemic Amyloidosis Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Systemic Amyloidosis Market Size by Application (2016-2027)
8.4 Asia-Pacific Systemic Amyloidosis Market Size by Region
8.4.1 Asia-Pacific Systemic Amyloidosis Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Systemic Amyloidosis Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Systemic Amyloidosis Market Size (2016-2027)
9.2 Latin America Systemic Amyloidosis Market Size by Type
9.2.1 Latin America Systemic Amyloidosis Market Size by Type (2016-2021)
9.2.2 Latin America Systemic Amyloidosis Market Size by Type (2022-2027)
9.2.3 Latin America Systemic Amyloidosis Market Size by Type (2016-2027)
9.3 Latin America Systemic Amyloidosis Market Size by Application
9.3.1 Latin America Systemic Amyloidosis Market Size by Application (2016-2021)
9.3.2 Latin America Systemic Amyloidosis Market Size by Application (2022-2027)
9.3.3 Latin America Systemic Amyloidosis Market Size by Application (2016-2027)
9.4 Latin America Systemic Amyloidosis Market Size by Country
9.4.1 Latin America Systemic Amyloidosis Market Size by Country (2016-2021)
9.4.2 Latin America Systemic Amyloidosis Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Systemic Amyloidosis Market Size (2016-2027)
10.2 Middle East & Africa Systemic Amyloidosis Market Size by Type
10.2.1 Middle East & Africa Systemic Amyloidosis Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Systemic Amyloidosis Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Systemic Amyloidosis Market Size by Type (2016-2027)
10.3 Middle East & Africa Systemic Amyloidosis Market Size by Application
10.3.1 Middle East & Africa Systemic Amyloidosis Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Systemic Amyloidosis Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Systemic Amyloidosis Market Size by Application (2016-2027)
10.4 Middle East & Africa Systemic Amyloidosis Market Size by Country
10.4.1 Middle East & Africa Systemic Amyloidosis Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Systemic Amyloidosis Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Celgene Corporation(Bristol-Myers Squibb)
11.1.1 Celgene Corporation(Bristol-Myers Squibb) Company Details
11.1.2 Celgene Corporation(Bristol-Myers Squibb) Business Overview
11.1.3 Celgene Corporation(Bristol-Myers Squibb) Systemic Amyloidosis Introduction
11.1.4 Celgene Corporation(Bristol-Myers Squibb) Revenue in Systemic Amyloidosis Business (2016-2021)
11.1.5 Celgene Corporation(Bristol-Myers Squibb) Recent Development
11.2 Prothena Corporation PLC
11.2.1 Prothena Corporation PLC Company Details
11.2.2 Prothena Corporation PLC Business Overview
11.2.3 Prothena Corporation PLC Systemic Amyloidosis Introduction
11.2.4 Prothena Corporation PLC Revenue in Systemic Amyloidosis Business (2016-2021)
11.2.5 Prothena Corporation PLC Recent Development
11.3 TheraPharm Deutschland GmbH
11.3.1 TheraPharm Deutschland GmbH Company Details
11.3.2 TheraPharm Deutschland GmbH Business Overview
11.3.3 TheraPharm Deutschland GmbH Systemic Amyloidosis Introduction
11.3.4 TheraPharm Deutschland GmbH Revenue in Systemic Amyloidosis Business (2016-2021)
11.3.5 TheraPharm Deutschland GmbH Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Details
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Systemic Amyloidosis Introduction
11.4.4 Johnson & Johnson Revenue in Systemic Amyloidosis Business (2016-2021)
11.4.5 Johnson & Johnson Recent Development
11.5 Amgen Inc.
11.5.1 Amgen Inc. Company Details
11.5.2 Amgen Inc. Business Overview
11.5.3 Amgen Inc. Systemic Amyloidosis Introduction
11.5.4 Amgen Inc. Revenue in Systemic Amyloidosis Business (2016-2021)
11.5.5 Amgen Inc. Recent Development
11.6 Onclave Therapeutics Limited
11.6.1 Onclave Therapeutics Limited Company Details
11.6.2 Onclave Therapeutics Limited Business Overview
11.6.3 Onclave Therapeutics Limited Systemic Amyloidosis Introduction
11.6.4 Onclave Therapeutics Limited Revenue in Systemic Amyloidosis Business (2016-2021)
11.6.5 Onclave Therapeutics Limited Recent Development
11.7 Pfizer Inc.
11.7.1 Pfizer Inc. Company Details
11.7.2 Pfizer Inc. Business Overview
11.7.3 Pfizer Inc. Systemic Amyloidosis Introduction
11.7.4 Pfizer Inc. Revenue in Systemic Amyloidosis Business (2016-2021)
11.7.5 Pfizer Inc. Recent Development
11.8 GlaxoSmithKline plc
11.8.1 GlaxoSmithKline plc Company Details
11.8.2 GlaxoSmithKline plc Business Overview
11.8.3 GlaxoSmithKline plc Systemic Amyloidosis Introduction
11.8.4 GlaxoSmithKline plc Revenue in Systemic Amyloidosis Business (2016-2021)
11.8.5 GlaxoSmithKline plc Recent Development
11.9 Alnylam Pharmaceuticals, Inc.
11.9.1 Alnylam Pharmaceuticals, Inc. Company Details
11.9.2 Alnylam Pharmaceuticals, Inc. Business Overview
11.9.3 Alnylam Pharmaceuticals, Inc. Systemic Amyloidosis Introduction
11.9.4 Alnylam Pharmaceuticals, Inc. Revenue in Systemic Amyloidosis Business (2016-2021)
11.9.5 Alnylam Pharmaceuticals, Inc. Recent Development
11.10 Takeda Pharmaceutical Company Limited
11.10.1 Takeda Pharmaceutical Company Limited Company Details
11.10.2 Takeda Pharmaceutical Company Limited Business Overview
11.10.3 Takeda Pharmaceutical Company Limited Systemic Amyloidosis Introduction
11.10.4 Takeda Pharmaceutical Company Limited Revenue in Systemic Amyloidosis Business (2016-2021)
11.10.5 Takeda Pharmaceutical Company Limited Recent Development
11.11 Allergan plc
11.11.1 Allergan plc Company Details
11.11.2 Allergan plc Business Overview
11.11.3 Allergan plc Systemic Amyloidosis Introduction
11.11.4 Allergan plc Revenue in Systemic Amyloidosis Business (2016-2021)
11.11.5 Allergan plc Recent Development
11.12 AbbVie Inc.
11.12.1 AbbVie Inc. Company Details
11.12.2 AbbVie Inc. Business Overview
11.12.3 AbbVie Inc. Systemic Amyloidosis Introduction
11.12.4 AbbVie Inc. Revenue in Systemic Amyloidosis Business (2016-2021)
11.12.5 AbbVie Inc. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Systemic Amyloidosis Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Primary Systemic Amyloidosis (PSA)
Table 3. Key Players of Secondary Systemic Amyloidosis
Table 4. Key Players of Others
Table 5. Global Systemic Amyloidosis Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Systemic Amyloidosis Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Systemic Amyloidosis Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Systemic Amyloidosis Market Share by Regions (2016-2021)
Table 9. Global Systemic Amyloidosis Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Systemic Amyloidosis Market Share by Regions (2022-2027)
Table 11. Systemic Amyloidosis Market Trends
Table 12. Systemic Amyloidosis Market Drivers
Table 13. Systemic Amyloidosis Market Challenges
Table 14. Systemic Amyloidosis Market Restraints
Table 15. Global Systemic Amyloidosis Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Systemic Amyloidosis Market Share by Players (2016-2021)
Table 17. Global Top Systemic Amyloidosis Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Systemic Amyloidosis as of 2020)
Table 18. Ranking of Global Top Systemic Amyloidosis Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Systemic Amyloidosis Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Systemic Amyloidosis Product Solution and Service
Table 22. Date of Enter into Systemic Amyloidosis Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Systemic Amyloidosis Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Systemic Amyloidosis Revenue Market Share by Type (2016-2021)
Table 26. Global Systemic Amyloidosis Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Systemic Amyloidosis Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Systemic Amyloidosis Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Systemic Amyloidosis Revenue Market Share by Application (2016-2021)
Table 30. Global Systemic Amyloidosis Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Systemic Amyloidosis Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Systemic Amyloidosis Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Systemic Amyloidosis Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Systemic Amyloidosis Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Systemic Amyloidosis Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Systemic Amyloidosis Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Systemic Amyloidosis Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Systemic Amyloidosis Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Systemic Amyloidosis Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Systemic Amyloidosis Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Systemic Amyloidosis Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Systemic Amyloidosis Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Systemic Amyloidosis Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Systemic Amyloidosis Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Systemic Amyloidosis Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Systemic Amyloidosis Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Systemic Amyloidosis Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Systemic Amyloidosis Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Systemic Amyloidosis Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Systemic Amyloidosis Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Systemic Amyloidosis Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Systemic Amyloidosis Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Systemic Amyloidosis Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Systemic Amyloidosis Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Systemic Amyloidosis Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Systemic Amyloidosis Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Systemic Amyloidosis Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Systemic Amyloidosis Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Systemic Amyloidosis Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Systemic Amyloidosis Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Systemic Amyloidosis Market Size by Country (2022-2027) & (US$ Million)
Table 62. Celgene Corporation(Bristol-Myers Squibb) Company Details
Table 63. Celgene Corporation(Bristol-Myers Squibb) Business Overview
Table 64. Celgene Corporation(Bristol-Myers Squibb) Systemic Amyloidosis Product
Table 65. Celgene Corporation(Bristol-Myers Squibb) Revenue in Systemic Amyloidosis Business (2016-2021) & (US$ Million)
Table 66. Celgene Corporation(Bristol-Myers Squibb) Recent Development
Table 67. Prothena Corporation PLC Company Details
Table 68. Prothena Corporation PLC Business Overview
Table 69. Prothena Corporation PLC Systemic Amyloidosis Product
Table 70. Prothena Corporation PLC Revenue in Systemic Amyloidosis Business (2016-2021) & (US$ Million)
Table 71. Prothena Corporation PLC Recent Development
Table 72. TheraPharm Deutschland GmbH Company Details
Table 73. TheraPharm Deutschland GmbH Business Overview
Table 74. TheraPharm Deutschland GmbH Systemic Amyloidosis Product
Table 75. TheraPharm Deutschland GmbH Revenue in Systemic Amyloidosis Business (2016-2021) & (US$ Million)
Table 76. TheraPharm Deutschland GmbH Recent Development
Table 77. Johnson & Johnson Company Details
Table 78. Johnson & Johnson Business Overview
Table 79. Johnson & Johnson Systemic Amyloidosis Product
Table 80. Johnson & Johnson Revenue in Systemic Amyloidosis Business (2016-2021) & (US$ Million)
Table 81. Johnson & Johnson Recent Development
Table 82. Amgen Inc. Company Details
Table 83. Amgen Inc. Business Overview
Table 84. Amgen Inc. Systemic Amyloidosis Product
Table 85. Amgen Inc. Revenue in Systemic Amyloidosis Business (2016-2021) & (US$ Million)
Table 86. Amgen Inc. Recent Development
Table 87. Onclave Therapeutics Limited Company Details
Table 88. Onclave Therapeutics Limited Business Overview
Table 89. Onclave Therapeutics Limited Systemic Amyloidosis Product
Table 90. Onclave Therapeutics Limited Revenue in Systemic Amyloidosis Business (2016-2021) & (US$ Million)
Table 91. Onclave Therapeutics Limited Recent Development
Table 92. Pfizer Inc. Company Details
Table 93. Pfizer Inc. Business Overview
Table 94. Pfizer Inc. Systemic Amyloidosis Product
Table 95. Pfizer Inc. Revenue in Systemic Amyloidosis Business (2016-2021) & (US$ Million)
Table 96. Pfizer Inc. Recent Development
Table 97. GlaxoSmithKline plc Company Details
Table 98. GlaxoSmithKline plc Business Overview
Table 99. GlaxoSmithKline plc Revenue in Systemic Amyloidosis Business (2016-2021) & (US$ Million)
Table 100. GlaxoSmithKline plc Recent Development
Table 101. Alnylam Pharmaceuticals, Inc. Company Details
Table 102. Alnylam Pharmaceuticals, Inc. Business Overview
Table 103. Alnylam Pharmaceuticals, Inc. Systemic Amyloidosis Product
Table 104. Alnylam Pharmaceuticals, Inc. Revenue in Systemic Amyloidosis Business (2016-2021) & (US$ Million)
Table 105. Alnylam Pharmaceuticals, Inc. Recent Development
Table 106. Takeda Pharmaceutical Company Limited Company Details
Table 107. Takeda Pharmaceutical Company Limited Business Overview
Table 108. Takeda Pharmaceutical Company Limited Systemic Amyloidosis Product
Table 109. Takeda Pharmaceutical Company Limited Revenue in Systemic Amyloidosis Business (2016-2021) & (US$ Million)
Table 110. Takeda Pharmaceutical Company Limited Recent Development
Table 111. Allergan plc Company Details
Table 112. Allergan plc Business Overview
Table 113. Allergan plc Systemic Amyloidosis Product
Table 114. Allergan plc Revenue in Systemic Amyloidosis Business (2016-2021) & (US$ Million)
Table 115. Allergan plc Recent Development
Table 116. AbbVie Inc. Company Details
Table 117. AbbVie Inc. Business Overview
Table 118. AbbVie Inc. Systemic Amyloidosis Product
Table 119. AbbVie Inc. Revenue in Systemic Amyloidosis Business (2016-2021) & (US$ Million)
Table 120. AbbVie Inc. Recent Development
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Systemic Amyloidosis Market Share by Type: 2020 VS 2027
Figure 2. Primary Systemic Amyloidosis (PSA) Features
Figure 3. Secondary Systemic Amyloidosis Features
Figure 4. Others Features
Figure 5. Global Systemic Amyloidosis Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Research Institutes Case Studies
Figure 9. Others Case Studies
Figure 10. Systemic Amyloidosis Report Years Considered
Figure 11. Global Systemic Amyloidosis Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Systemic Amyloidosis Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Systemic Amyloidosis Market Share by Regions: 2020 VS 2027
Figure 14. Global Systemic Amyloidosis Market Share by Regions (2022-2027)
Figure 15. Global Systemic Amyloidosis Market Share by Players in 2020
Figure 16. Global Top Systemic Amyloidosis Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Systemic Amyloidosis as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Systemic Amyloidosis Revenue in 2020
Figure 18. Global Systemic Amyloidosis Revenue Market Share by Type (2016-2021)
Figure 19. Global Systemic Amyloidosis Revenue Market Share by Type (2022-2027)
Figure 20. North America Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Systemic Amyloidosis Market Share by Type (2016-2027)
Figure 22. North America Systemic Amyloidosis Market Share by Application (2016-2027)
Figure 23. North America Systemic Amyloidosis Market Share by Country (2016-2027)
Figure 24. United States Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Systemic Amyloidosis Market Share by Type (2016-2027)
Figure 28. Europe Systemic Amyloidosis Market Share by Application (2016-2027)
Figure 29. Europe Systemic Amyloidosis Market Share by Country (2016-2027)
Figure 30. Germany Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Systemic Amyloidosis Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Systemic Amyloidosis Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Systemic Amyloidosis Market Share by Region (2016-2027)
Figure 40. China Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Systemic Amyloidosis Market Share by Type (2016-2027)
Figure 48. Latin America Systemic Amyloidosis Market Share by Application (2016-2027)
Figure 49. Latin America Systemic Amyloidosis Market Share by Country (2016-2027)
Figure 50. Mexico Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Systemic Amyloidosis Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Systemic Amyloidosis Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Systemic Amyloidosis Market Share by Country (2016-2027)
Figure 56. Turkey Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Systemic Amyloidosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Celgene Corporation(Bristol-Myers Squibb) Revenue Growth Rate in Systemic Amyloidosis Business (2016-2021)
Figure 60. Prothena Corporation PLC Revenue Growth Rate in Systemic Amyloidosis Business (2016-2021)
Figure 61. TheraPharm Deutschland GmbH Revenue Growth Rate in Systemic Amyloidosis Business (2016-2021)
Figure 62. Johnson & Johnson Revenue Growth Rate in Systemic Amyloidosis Business (2016-2021)
Figure 63. Amgen Inc. Revenue Growth Rate in Systemic Amyloidosis Business (2016-2021)
Figure 64. Onclave Therapeutics Limited Revenue Growth Rate in Systemic Amyloidosis Business (2016-2021)
Figure 65. Pfizer Inc. Revenue Growth Rate in Systemic Amyloidosis Business (2016-2021)
Figure 66. GlaxoSmithKline plc Revenue Growth Rate in Systemic Amyloidosis Business (2016-2021)
Figure 67. Alnylam Pharmaceuticals, Inc. Revenue Growth Rate in Systemic Amyloidosis Business (2016-2021)
Figure 68. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Systemic Amyloidosis Business (2016-2021)
Figure 69. Allergan plc Revenue Growth Rate in Systemic Amyloidosis Business (2016-2021)
Figure 70. AbbVie Inc. Revenue Growth Rate in Systemic Amyloidosis Business (2016-2021)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
世界の全身放射線療法市場規模・現状・予測（2021年-2027年） A type of radiation therapy in which a radioactive substance, such as radioactive iodine or a radioactively labeled monoclonal antibody, is swallowed or injected into the body and travels through the blood, locating and killing tumor cells. Market Analysis and Insights: Global Systemic Radiotherapy …- 世界の全身性強皮症治療市場規模・現状・予測（2021年-2027年） Systemic scleroderma is an autoimmune disorder that affects the skin and internal organs . It is characterized by the buildup of scar tissue (fibrosis) in the skin and other organs. The fibrosis is caused by the body's production of too much collagen, which normally strengthens and supports connecti…
- 世界の全身性強皮症治療薬市場規模・現状・予測（2021年-2027年） Systemic scleroderma is an autoimmune disorder that affects the skin and internal organs . It is characterized by the buildup of scar tissue (fibrosis) in the skin and other organs. The fibrosis is caused by the body's production of too much collagen, which normally strengthens and supports connecti…
- 世界の全身性抗生物質市場規模・現状・予測（2021年-2027年） It refers to a class of secondary metabolites produced by microorganisms (including bacteria, fungi, actinomycetes) or higher animals and plants that have anti-pathogens or other activities during their life, and can interfere with the development of other living cells. substance. Market Analysis an…
- 世界の全身性炎症反応症候群治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Systemic Inflammatory Response Syndrome Treatment Market The global Systemic Inflammatory Response Syndrome Treatment market size is projected to reach US$ 11740 million by 2027, from US$ 8346.7 million in 2020, at a CAGR of 4.5% during 2021-2027. With industry-s…